This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The Equity and Income Fund earned 0.2% in the quarter, while the Lipper Balanced Fund Index, the Fund’s performance benchmark, gained 1.1%.
PM C.WSA DOV.WI NOV TEL CVS FNF BAC C.WS.B CHTR APY.WI GM.WS.A FNFV C.WS.A GM.WS.B GM.WS.C C.PRP DOV C.PRU GM ORCL C.PRS LBRDB BAC C C.PRL AAL C.PRJ C.PRK BHGE COMM MA ARNC C.PRG TWC LBRDK C.PRC BHI C.PRPCL CGBBW OCLCF JLL LBRDA FL APY GM.WSB UNH
THE WOODLANDS, Texas, July 05, 2018 (GLOBE NEWSWIRE) -- Apergy Corporation (“Apergy”) (NYSE:APY) announced today that it will release its second quarter 2018 operating results on Wednesday, July 25, 2018 after the market closes. The Company has scheduled a conference call for Thursday, July 26, 2018 at 8 a.m. Central Time (9 a.m. Eastern Time) to discuss the results.
THE WOODLANDS, Texas, June 08, 2018 (GLOBE NEWSWIRE) -- Apergy Corporation (“Apergy”) (NYSE:APY) announced today that Sivasankaran "Soma" Somasundaram, President and Chief Executive Officer, and Jay Nutt, Senior Vice President and Chief Financial Officer, will attend and meet with investors at the Wells Fargo 2018 West Coast Energy Conference in San Francisco, California on June 12, 2018. The presentation to be used in the investor meetings will be available on Tuesday, June 12, 2018, prior to the commencement of the meetings under the “Investors – Media Files” tab of our website at http://www.
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ APY.WI WFC.PRP WFC.PRO WFC.PRN APY WFC.PRY WFC.PRX WFC.PRW WFC.PRV
Apergy Corp. provides technologies that help companies drill for and produce oil and gas. Its products include artificial lift equipment and solutions, rod pumping systems, electric submersible pump systems, gas lift systems, hydraulic lift and pump services, progressive cavity pumps and drive systems and plunger lift systems, and polycrystalline diamond cutters for drilling. The firm operates through two segments: Production & Automation Technologies and Drilling Technologies.
Dover Corporation (DOV - Free Report) has successfully completed the spin-off of its upstream energy businesses — Wellsite — which has been later named Apergy. Now on, Dover will be a standalone company focused on industrial products and manufacturing equipment, while Apergy will be an independent public company. Spin-off History In December 2017, Dover announced a tax-free spin-off of its upstream energy businesses within the Energy segment, which comprises Dover Artificial Lift, Dover Energy Automation, and US Synthetic.
ATLKY ATLKF ATTLF APY.WI DOV.WI GGG ATLCY DOV AIT DTK APY
THE WOODLANDS, Texas, May 09, 2018 (GLOBE NEWSWIRE) -- S&P Dow Jones Indices, a division of S&P Global Inc., announced on May 2, 2018 that Apergy Corporation (“Apergy”) (NYSE:APY), a leading provider of highly engineered equipment and technologies that help companies drill for and produce oil and gas safely and efficiently around the world, will be added to the S&P 400 MidCap index prior to the open of trading on Thursday, May 10, 2018.
4h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
5h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET